Small-molecule inhibitors of protein–protein interactions: progressing towards the dream

@article{Arkin2004SmallmoleculeIO,
  title={Small-molecule inhibitors of protein–protein interactions: progressing towards the dream},
  author={M. Arkin and J. Wells},
  journal={Nature Reviews Drug Discovery},
  year={2004},
  volume={3},
  pages={301-317}
}
  • M. Arkin, J. Wells
  • Published 2004
  • Computer Science, Medicine
  • Nature Reviews Drug Discovery
Protein–protein interactions have a key role in most biological processes, and offer attractive opportunities for therapeutic intervention. Developing small molecules that modulate protein–protein interactions is difficult, owing to issues such as the lack of well-defined binding pockets. Nevertheless, there has been important progress in this endeavour in recent years. Here, we use illustrative examples to discuss general strategies for addressing the challenges inherent in the discovery and… Expand

Figures, Tables, and Topics from this paper

Inhibiting protein-protein interactions using designed molecules.
TLDR
Highlights of recent advances involve peptide-based inhibitors, including sidechain and backbone cross-linked agents, and peptide scaffolds, as well as small-molecule inhibitors of protein-protein interactions, such as those containing terephthalate or bis-imidazole scaffolds. Expand
Rational design of protein–protein interaction inhibitors
TLDR
This review highlights the very recent developments in the rational design of protein–protein interaction inhibitors, which have recently reached clinical trials. Expand
Strategies for targeting protein-protein interactions with synthetic agents.
TLDR
This review discusses the strategies for targeting protein-protein interactions and the state of the art in the rational design of molecules that mimic the structures and functions of their natural targets. Expand
Development of small molecules designed to modulate protein–protein interactions
TLDR
A general approach is described based on the “privileged-structure hypothesis” – that any organic templates capable of mimicking surfaces of protein-recognition motifs are potential privileged scaffolds as protein-complex antagonists – to address the challenges inherent in the discovery of small-molecule inhibitors of protein–protein interactions. Expand
Overview of Protein-Protein Interactions and Small-Molecule Inhibitors Under Clinical Development
Protein-protein interactions (PPIs) provide a rich source of drug targets for the development of new generation of clinical therapeutics. However, targeting PPIs by small-molecule inhibitors remainsExpand
Targeting protein-protein interactions for drug discovery.
  • D. Fry
  • Computer Science, Medicine
  • Methods in molecular biology
  • 2015
TLDR
These experiences are starting to provide general strategies and tools to help overcome the problems inherent in pursuing protein-protein interaction targets and should improve the rate of success as these systems are pursued in the future. Expand
Emerging classes of protein-protein interaction inhibitors and new tools for their development.
TLDR
Protein translocation assays provide a unique new tool for identifying, profiling, and optimizing SMPPIIs. Expand
Protein-Protein Interaction Inhibitors: Case Studies on Small Molecules and Natural Compounds
Many biological functions involve the formation of protein–protein complexes, and the inhibition of this process has garnered significant interest in pharmaceutical research investigating novelExpand
Prospects of Modulating Protein–Protein Interactions
This chapter provides an overview of the approaches used for the design of chemical modulators of protein–protein interactions using computational methods in combination with experimental assays.Expand
Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles
TLDR
Recent work towards developing small molecule inhibitors of amyloid-β and α-synuclein aggregation, inhibitors of critical components of G-protein-signaling pathways, and PDZ domain inhibitors are focused upon. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 219 REFERENCES
Inhibitors of protein-protein interactions
TLDR
Examples are presented of currently marketed drugs, compounds in clinical development and lead molecules in research programmes, which have been identified as inhibitors of protein-protein interactions. Expand
Small molecule antagonists of proteins.
TLDR
The progress in identifying and designing small molecule protein inhibitors, with particular attention to those that block protein-protein interactions, is reviewed. Expand
Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs.
  • J. Way
  • Chemistry, Medicine
  • Current opinion in chemical biology
  • 2000
TLDR
A novel pharmaceutical development strategy to block protein interactions is emerging: targeted covalent modification to sterically block interactions with small-molecule drugs. Expand
Protein-protein interactions: lessons learned.
TLDR
This review examines P-P interactions with particular emphasis on the discovery of new anti-tumor drugs, including underlying physical forces that determine affinity and specificity and discusses classical and newer strategies used to discover inhibitors of P-p interactions. Expand
Modulation of protein-protein interactions with small organic molecules.
  • T. Berg
  • Chemistry, Medicine
  • Angewandte Chemie
  • 2003
TLDR
A number of protein-protein interactions that are considered to be pharmaceutical targets are presented, which will familiarize the reader with the strategies that have been employed for the successful identification of small molecule modulators of these protein- protein interactions. Expand
Protein-protein interfaces: mimics and inhibitors.
  • A. Cochran
  • Biology, Medicine
  • Current opinion in chemical biology
  • 2001
Many biological processes are mediated by specific molecular recognition between proteins. However, the thermodynamic and structural 'rules' for such recognition are incompletely understood, as isExpand
A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors.
TLDR
A novel method of ligand validation and optimization, which is based on the combination of structural and computational approaches, is presented, which successfully used the basis for structure-activity relationships of previously selected small molecule inhibitors of the antiapoptotic protein Bcl-xL and identified new members of this inhibitor family. Expand
Implications of protein flexibility for drug discovery
  • S. Teague
  • Chemistry, Medicine
  • Nature Reviews Drug Discovery
  • 2003
TLDR
This work has shown that protein flexibility allows increased affinity to be achieved between a drug and its target, crucial, because the lipophilicity and number of polar interactions allowed for an oral drug is limited by absorption, distribution, metabolism and toxicology considerations. Expand
Discovery of a potent small molecule IL-2 inhibitor through fragment assembly.
TLDR
Using a site-directed fragment discovery method called tethering, a 60 nM small molecule antagonist of a cytokine/receptor interaction (IL-2/IL2Ralpha) with cell-based activity is identified and represents the highest affinity inhibitor reported against this protein-protein target class. Expand
The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules.
TLDR
Recent advances in the use of chemical approaches in discovering and studying small molecules targeted to proteins of the Bcl-2 and IAP families provide the tools and model systems to probe the basic mechanism of molecule recognition underling the life and death of cells. Expand
...
1
2
3
4
5
...